Documents A to Z

| 1 | 2 | 3 | 4 | 5 | 7 | 8 | 9 | A | B | C | D | E | F | G | H | I | J | L | M | N | O | P | Q | R | S | T | U | V | W | Z

M

Notes on the design of bioequivalence study: Emtricitabine/Tenofovir Disoproxil Fumarate/Efavirenz PDF

M

Notes on the design of bioequivalence study: emtricitabine/tenofovir/dolutegravir PDF

M

Notes on the design of bioequivalence study: emtricitabine/tenofovir/efavirenz PDF

M

Notes on the design of bioequivalence study: entecavir PDF

M

Notes on the design of bioequivalence study: ethambutol (6 February 2024) PDF

M

Notes on the design of bioequivalence study: ethambutol/isoniazid/pyrazinamide/rifampicin PDF

M

Notes on the design of bioequivalence study: ethambutol/isoniazid/rifampicin PDF

M

Notes on the design of bioequivalence study: ethinylestradiol/desogestrel PDF

M

Notes on the design of bioequivalence study: ethinylestradiol/levonorgestrel PDF

M

Notes on the design of bioequivalence study: ethionamide PDF

M

Notes on the design of bioequivalence study: etonogestrel implant PDF

M

Notes on the design of bioequivalence study: fexinidazole (5 May 2025) PDF

M

Notes on the design of bioequivalence study: flucytosine (5 May 2025) PDF

M

Notes on the design of bioequivalence study: glecaprevir/pibrentasvir PDF

M

Notes on the design of bioequivalence study: isoniazid PDF

M

Notes on the design of bioequivalence study: isoniazid/pyrazinamide/rifampicin PDF

M

Notes on the design of bioequivalence study: isoniazid/rifampicin PDF

M

Notes on the design of bioequivalence study: isoniazid/rifapentine PDF

M

Notes on the design of bioequivalence study: isoniazid/rifapentine/moxifloxacin PDF

M

Notes on the design of bioequivalence study: isoniazid/rifapentine/moxifloxacin/pyrazinamide PDF

M

Notes on the design of bioequivalence study: ivermectin PDF

M

Notes on the design of bioequivalence study: lamivudine PDF

M

Notes on the Design of Bioequivalence Study: Lamivudine / Abacavir / Dolutegravir PDF

M

Notes on the design of bioequivalence study: lamivudine/tenofovir/dolutegravir PDF

M

Notes on the design of bioequivalence study: lamivudine/tenofovir/efavirenz PDF

M

Notes on the design of bioequivalence study: lamivudine/zidovudine PDF

M

Notes on the design of bioequivalence study: ledipasvir PDF

M

Notes on the design of bioequivalence study: ledipasvir/sofosbuvir PDF

M

Notes on the design of bioequivalence study: lenacapavir sodium PDF

M

Notes on the design of bioequivalence study: levofloxacin PDF

M

Notes on the design of bioequivalence study: levonorgestrel PDF

M

Notes on the design of bioequivalence study: levonorgestrel implant PDF

M

Notes on the design of bioequivalence study: levonorgestrel intra-uterine system PDF

M

Notes on the design of bioequivalence study: linezolid PDF

M

Notes on the design of bioequivalence study: lopinavir/ritonavir PDF

M

Notes on the design of bioequivalence study: mebendazole PDF

M

Notes on the design of bioequivalence study: medroxyprogesterone acetate PDF

M

Notes on the design of bioequivalence study: medroxyprogesterone acetate/estradiol cypionate PDF

M

Notes on the design of bioequivalence study: mefloquine PDF

M

Notes on the design of bioequivalence study: mifepristone PDF

M

Notes on the design of bioequivalence study: miltefosine PDF

M

Notes on the design of bioequivalence study: misoprostol PDF

M

Notes on the design of bioequivalence study: molnupiravir PDF

M

Notes on the Design of Bioequivalence Study: Moxidectin PDF

M

Notes on the design of bioequivalence study: moxifloxacin PDF

M

Notes on the design of bioequivalence study: nicotine chewing gum PDF

M

Notes on the design of bioequivalence study: nicotine transdermal patch PDF

M

Notes on the design of bioequivalence study: nirmatrelvir + ritonavir PDF

M

Notes on the design of bioequivalence study: nitrofurantoin PDF

M

Notes on the design of bioequivalence study: nitrofurantoin PDF